FY2025 EPS Estimates for Alkermes Reduced by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS) – Leerink Partnrs reduced their FY2025 earnings per share estimates for Alkermes in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.50 for the year, down from their prior forecast of $1.55. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.84 EPS.

Other analysts have also issued research reports about the company. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price target (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a report on Friday, October 25th. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and increased their price objective for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. Mizuho increased their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. decreased their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Alkermes Stock Performance

Shares of ALKS stock opened at $31.91 on Thursday. The stock has a fifty day moving average of $29.74 and a 200 day moving average of $28.25. Alkermes has a 52 week low of $22.90 and a 52 week high of $32.88. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 1.56 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insiders Place Their Bets

In other news, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the transaction, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Craig C. Hopkinson sold 10,471 shares of Alkermes stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total value of $309,208.63. Following the sale, the executive vice president now directly owns 99,238 shares in the company, valued at $2,930,498.14. This trade represents a 9.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 147,738 shares of company stock valued at $4,572,904. Insiders own 4.89% of the company’s stock.

Institutional Trading of Alkermes

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC bought a new stake in Alkermes in the 3rd quarter worth approximately $29,000. Blue Trust Inc. increased its stake in Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock worth $49,000 after acquiring an additional 1,629 shares during the last quarter. GAMMA Investing LLC increased its stake in Alkermes by 83.8% in the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company’s stock worth $118,000 after acquiring an additional 1,917 shares during the last quarter. Archer Investment Corp increased its position in shares of Alkermes by 28.6% during the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock valued at $126,000 after purchasing an additional 1,000 shares during the last quarter. Finally, KBC Group NV increased its position in shares of Alkermes by 18.8% during the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock valued at $137,000 after purchasing an additional 774 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.